Bio-Techne (NASDAQ:TECH – Get Rating) and BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
23.9% of Bio-Techne shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get
Bio-Techne alerts:
Valuation and Earnings
This table compares Bio-Techne and BiondVax Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Bio-Techne | $1.12 billion | 11.05 | $272.05 million | $1.78 | 44.20 |
| BiondVax Pharmaceuticals | N/A | N/A | -$12.85 million | ($4.04) | -0.64 |
Bio-Techne has higher revenue and earnings than BiondVax Pharmaceuticals. BiondVax Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Bio-Techne has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Bio-Techne and BiondVax Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Bio-Techne | 0 | 2 | 5 | 0 | 2.71 |
| BiondVax Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Bio-Techne currently has a consensus target price of $107.86, indicating a potential upside of 37.09%. Given Bio-Techne's higher probable upside, research analysts clearly believe Bio-Techne is more favorable than BiondVax Pharmaceuticals.
Profitability
This table compares Bio-Techne and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Bio-Techne | 26.13% | 16.37% | 12.16% |
| BiondVax Pharmaceuticals | N/A | -230.46% | -35.35% |
Summary
Bio-Techne beats BiondVax Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Bio-Techne
(Get Rating)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
